Table 5.
Analysis of genetics effect on malaria treatment outcome (risk of recrudescence) in pregnant women
| Genotype | No of patients | No. of recrudescence | Percentage (%) | P value (log-rank test) |
|---|---|---|---|---|
| CYP2B6*6 | 0.676 | |||
| CYP2B6*1/*1 | 35 | 1 | 2.8 | |
| CYP2B6*1/*6 | 32 | 2 | 6.5 | |
| CYP2B6*6/*6 | 11 | 1 | 9.0 | |
| CYP2B6*18 | 0.605 | |||
| CYP2B6*1/*1 | 72 | 5 | 6.9 | |
| CYP2B6*1/*18 | 14 | 2 | 14.2 | |
| CYP2B6*18/*18 | 1 | 0 | 0 | |
| CYP3A4*1B | 0.018 | |||
| CYP3A4*1/*1 | 2 | 1 | 50 | |
| CYP3A4*1/*1B | 37 | 3 | 8.1 | |
| CYP3A4*1B/*1B | 49 | 3 | 6.1 | |
| CYP3A5*3 | 0.087 | |||
| CYP3A5*1/*1 | 48 | 3 | 6.2 | |
| CYP3A5*1/*3 | 36 | 3 | 8.3 | |
| CYP3A5*3/*3 | 2 | 1 | 50 | |
| CYP3A5*6 | 0.645 | |||
| CYP3A5*1/*1 | 57 | 4 | 7.0 | |
| CYP3A5*1/*6 | 26 | 3 | 11.5 | |
| CYP3A5*6/*6 | 5 | 0 | 0 | |
| CYP3A5*7 | 0.134 | |||
| CYP3A5*1/*1 | 66 | 7 | 10.6 | |
| CYP3A5*1/*7 | 20 | 0 | 0 | |
| CYP3A5*7/*7 | – | – | – | |
| ABCB1 rs3842 | 0.462 | |||
| A/A | 12 | 0 | 0 | |
| A/G | 25 | 3 | 12 | |
| G/G | 51 | 4 | 7.8 |